Background: Alzheimer's disease (AD) is a progressive neurological disorder with an unclear cause, and its amyloid and tau hypotheses need deeper investigation to understand their link to genetic variants and AD outcomes. To bridge this gap, we conduct a mediation analysis using the genotyping, amyloid and tau imaging, and cognitive data from Alzheimer's Disease Neuroimaging Initiative (ADNI) to delineate specific mediation pathways from genetic variants such as single nucleotide polymorphisms (SNPs), to regional amyloid/tau protein aggregation in the brain, and to cognitive outcomes.
Method: ADNI provides genotyped data and harmonized phenotypes. We further imputed, harmonized, annotated the genotyping data. Post-quality control and subject matching resulted in 1,051 individuals for amyloid and 525 for tau imaging measurements. We first conducted genome-wide association study (GWAS) on 5,302,064 variants to prioritize SNPs significantly associated with cognitive scores. Subsequently, we employed a mediation model to explore how regional amyloid and tau imaging measures mediate the genetic effects on cognitive scores. Specifically, we used prioritized SNPs from GWAS as exposure, two cognitive scores (ADAS-Cog13 and MMSE) as outcomes, and amyloid and tau imaging measures from 68 cortical regions as mediators. Additionally, we contrasted results from GWAS-identified SNPs with five candidate AD SNPs.
Result: We assessed amyloid and tau aggregation in 68 cortical brain regions as mediators for SNP effects on cognitive scores; see Figure 1 for top findings. After Bonferroni correction, we found 9,551, 34,402, 5,636, and 193,002 mediation relationships for SNP-amyloid-ADAS13, SNP-amyloid-MMSE, SNP-tau-ADAS13, and SNP-tau-MMSE respectively. Tau aggregation demonstrated a broader impact on AD across cortical regions compared to amyloid. Although 4 of the candidate AD SNPs showed no signal, one of them, rs429358, demonstrated strong amyloid and tau mediated genetic effects on cognitive outcomes. Our results also showed that amyloid and tau hypotheses have different regional mediation patterns (Figure 2). For example, bankstss region only influences the tau pathway, while caudal anterior cingulate only affects the amyloid pathway.
Conclusion: Our genome-wide mediation analysis has identified top cortical regions and SNPs associated with amyloid- and tau-mediated cognitive declines in AD. These results yield new insights into AD etiology linking genetic determinants, cellular hallmarks, and phenotypic outcomes.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/alz.089710 | DOI Listing |
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11715476 | PMC |
J Alzheimers Dis
January 2025
Division of Cardiothoracic Surgery, Rhode Island Hospital, Alpert Medical School of Brown University, Providence, RI, USA.
Background: Alzheimer's disease (AD) is a complex neurodegenerative disease marked by increased amyloid-β (Aβ) deposition, tau hyperphosphorylation, impaired energy metabolism, and chronic ischemia-type injury. Cerebral microvascular dysfunction likely contributes to AD pathology, but its precise pathogenic role has been poorly defined.
Objective: To examine microvascular reactivity to endothelium-dependent vasodilators and small conductance calcium-activated potassium (SK) channel activity in an intracerebral streptozotocin (STZ)-induced AD mouse model.
Proteomics
January 2025
Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Alzheimer's disease (AD) is a leading cause of dementia, but the pathogenesis mechanism is still elusive. Advances in proteomics have uncovered key molecular mechanisms underlying AD, revealing a complex network of dysregulated pathways, including amyloid metabolism, tau pathology, apolipoprotein E (APOE), protein degradation, neuroinflammation, RNA splicing, metabolic dysregulation, and cognitive resilience. This review examines recent proteomic findings from AD brain tissues and biological fluids, highlighting potential biomarkers and therapeutic targets.
View Article and Find Full Text PDFCNS Neurol Disord Drug Targets
January 2025
School of Medicine, Foshan University, Foshan, 528000, China.
Introduction: Neuroinflammation derived from the activation of the microglia is considered a vital pathogenic factor of Alzheimer's Disease (AD). T-006, a tetramethylpyrazine derivative, has been found to alleviate cognitive deficits via inhibiting tau expression and phosphorylation in AD transgenic mouse models. Recently, T-006 has been proven to dramatically decrease the levels of total Amyloid β (Aβ) peptide and Glial Fibrillary Acidic Protein (GFAP) and suppress the expression of ionized calcium binding adaptor molecule-1 (Iba-1) in APP/PS1 mice.
View Article and Find Full Text PDFRSC Med Chem
December 2024
Pharmaceutical Chemistry Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Sciences Pilani Pilani Campus, Vidya Vihar Pilani 333031 RJ India +91 1596 244183 +91 1596 255 506.
Alzheimer's disease (AD) is a complex, incurable neurological condition characterized by cognitive decline, cholinergic neuron reduction, and neuronal loss. Its exact pathology remains uncertain, but multiple treatment hypotheses have emerged. The current treatments, single or combined, alleviate only symptoms and struggle to manage AD due to its multifaceted pathology.
View Article and Find Full Text PDFJ Neuropsychiatry Clin Neurosci
January 2025
Department of Psychology, California State University, San Bernardino (Ryczek, Rivas, Hemphill, Zanotelli, Renteria, Jones); Department of Neurology, Division of Movement Disorders, Loma Linda University Health System, Loma Linda, Calif. (Dashtipour); Center on Aging, California State University, San Bernardino (Jones).
Objective: Cognitive impairment is a common nonmotor symptom among individuals with Parkinson's disease (PD). Although cognitive impairment generally develops progressively, individuals with PD-associated mild cognitive impairment (PD-MCI) may revert to being cognitively normal (CN), which is referred to as PD-MCI reversion. Previous studies are inconsistent in whether PD-MCI reverters are at greater risk for PD-MCI recurrence relative to CN individuals.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!